ArticlePediatric radiology2026
Assessment of ultrasound ovarian-adnexal reporting & data system (O-RADS) for pediatric patients.
Article in Pediatric radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- O-RADS for assessment of adnexal lesions: current status, challenges and future directions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Age-stratified diagnostic performance of the ovarian-adnexal reporting and data system for adnexal masses: a focus on school-age children, early, and middle adolescents.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian-Adnexal Reporting & Data System Ultrasound (O-RADS US) is a validated scoring system in adult women with adnexal lesions to help assess the risk of potential malignancy. Limited data exists for children in whom malignancy is rare.
objectiveTo evaluate inter-radiologist agreement and diagnostic performance when using the O-RADS US in pediatric patients with ovarian lesions. MATERIALS AND
methodsRetrospective IRB-approved study included pelvic ultrasounds (US) from 2015 to 2020 in pediatric patients (<18 years). Pelvic US with ovarian lesions measuring >3 cm in premenarchal patients and >5 cm in menarchal patients were included. Three pediatric radiologists reviewed each US and recorded imaging characteristics and O-RADS classification. Diagnostic performance was assessed, and agreement among radiologists was calculated.
resultsIn total, 160 pelvic US exams were included in 160 patients, with a mean patient age of 12.1 years (SD=4.9). Most lesions were classified as O-RADS 2 (almost certainly benign), and fewer cases as O-RADS 4 (intermediate risk) or O-RADS 5 (high risk). Inter-radiologist agreement for O-RADS category was moderate (κ=0.42). Diagnostic performance of US O-RADS demonstrated high sensitivity and NPV (100% for all three reviewers). Specificities were 74-82%, and PPV was low at 5-7% for distinguishing malignant/borderline lesions from benign lesions.
conclusionsApplication of the O-RADS US system in pediatric patients may be challenging due to the low overall malignancy rate. Nevertheless, an O-RADS 2 classification provides meaningful reassurance, reflecting minimal malignancy risk in children. Larger studies are needed to determine the clinical utility of O-RADS US and whether pediatric-specific modifications are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.